JERUSALEM--(BUSINESS WIRE)--Feb. 11, 2016--
In accordance with Section 203.01 of the New York Stock Exchange Listed
Company Manual, Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA)
(“Teva”) announced today that it has filed its 2015 Annual Report on
Form 20-F with the U.S. Securities and Exchange Commission. The Annual
Report can be found on the company’s website at www.tevapharm.com
as well as on the SEC website at www.sec.gov.
In addition, security holders may request a hard copy of the Annual
Report, which includes the company’s complete audited financial
statements, free of charge. Requests can be made by contacting Teva
Investor Relations at 1090 Horsham Road, North Wales PA, 19454 or by
phone at (215) 591-8912.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading
global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions used by millions of patients every
day. Headquartered in Israel, Teva is the world’s largest generic
medicines producer, leveraging its portfolio of more than 1,000
molecules to produce a wide range of generic products in nearly every
therapeutic area. In specialty medicines, Teva has a world-leading
position in innovative treatments for disorders of the central nervous
system, including pain, as well as a strong portfolio of respiratory
products. Teva integrates its generics and specialty capabilities in its
global research and development division to create new ways of
addressing unmet patient needs by combining drug development
capabilities with devices, services and technologies. Teva's net
revenues in 2015 amounted to $19.7 billion. For more information, visit www.tevapharm.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160211006504/en/
Source: Teva Pharmaceutical Industries Ltd.
For Teva Pharmaceutical Industries Ltd.
IR:
United States
Kevin
C. Mannix, 215-591-8912
or
United States
Ran
Meir, 215-591-3033
or
Israel
Tomer Amitai,
972 (3) 926-7656
or
PR:
Israel
Iris Beck Codner,
972 (3) 926-7687
or
United States
Denise Bradley,
215-591-8974